Omnicell, Inc.

Omnicell, Inc.

39.41
USD
+3.95
(+11.14%)
0.85EPS
48.19P/E
1.89BMarket Cap
Feb 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.96
12.37
13.51
19.25
19.01
20.06
21.63
20.95
26.04
29.19
25.37
24.15
25.78
- -
Basic EPS, GAAP
0.69
0.86
0.86
0.27
0.81
0.96
1.48
0.76
1.79
0.13
-0.45
0.27
0.04
- -
Free Cash Flow per Basic Share
1
1.19
0.51
0.57
-0.15
1.26
2.01
3.08
3.99
0.38
2.79
2.93
1.51
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.97
10.89
11.3
11.78
14.42
16.85
20.06
22.61
25.96
25.26
26.11
26.81
27.36
- -
Tangible Book Value per Share
4
4.61
3.9
-3.27
0.26
3.55
7.09
4.81
0.75
1.61
3.85
5.65
5.99
- -
Basic Weighted Avg Shares
35
36
36
36
37
39
41
43
43
44
45
46
46
45
Sales/Revenue/Turnover
381
441
485
696
713
787
897
892
1,132
1,296
1,147
1,112
1,185
- -
Operating Margin (%)
9.27
11.25
9.33
3.08
1.56
5.64
8.73
3.98
7.91
-0.18
-3.04
0.03
0.44
- -
Depreciation Expense
18
20
26
58
52
51
64
72
85
99
96
90
87
- -
Net Income, GAAP
24
31
31
10
31
38
61
32
78
6
-20
13
2
- -
Effective Tax Rate (%)
31.55
37.08
33.48
24.82
- -
- -
17.04
- -
- -
- -
- -
51.04
81.88
- -
Profit Margin (%)
6.3
6.92
6.35
1.4
4.28
4.79
6.84
3.61
6.88
0.44
-1.78
1.13
0.17
- -
Working Capital
141
171
139
134
147
193
246
553
-95
453
560
220
203
- -
LT Debt
- -
- -
- -
246
195
135
101
516
40
606
604
198
192
- -
Total Equity
349
390
402
432
554
680
845
968
1,147
1,130
1,189
1,243
1,232
- -
Return on Invested Capital (%)
7.35
8.42
8.14
2.96
- -
- -
7.33
- -
- -
- -
- -
0.01
0.06
- -
Return on Capital (%)
7.33
8.26
7.76
1.79
- -
- -
6.93
- -
- -
- -
- -
0.73
0.13
- -
Return on Common Equity (%)
7.3
8.26
7.76
2.34
6.19
6.12
8.05
3.55
7.36
0.5
-1.76
1.03
0.17
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
12
11
- -
LT Borrowings
168
168
- -
LT Finance Leases
23
20
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
46
46
Market Capitalization
1,518
1,894
1,563

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
722
735
- -
Cash, Cash Equivalents & STI
254
307
- -
Accounts Receivable, Net
250
227
- -
Inventories
99
97
- -
Total Current Liabilities
483
447
- -
Payables & Accruals
139
130
- -
ST Debt
12
11
- -
Deferred Revenue
286
245
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.31%
5.19%
-0.92%
Free Cash Flow
-41.8%
108.1%
-48.59%
Net Income, GAAP
-47.35%
-131.35%
-83.62%
Sales/Revenue/Turnover
10.33%
6.67%
6.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
246
277
282
307
1,112
2025
270
291
311
314
1,185
2026
310
312
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
0.08
0.19
0.34
0.27
2025
-0.15
0.12
0.12
-0.05
0.04
2026
0.25
0.53
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Randall A. Lipps
Full Time Employees
3,580
Sector
Technology services
Industry
Information technology services
Address
4220 North Freeway Fort Worth TX United States 76137
IPO Date
Aug 7, 2001
Business
Omnicell, Inc. is a healthcare technology company specializing in medication management solutions and adherence tools designed to enhance healthcare delivery and operational efficiency. The company offers an extensive portfolio that includes automated medication dispensing systems; pharmacy automation equipment; medication adherence packaging; analytics and inventory management software; point-of-care pharmacy automation; adherence packaging systems under the MyMD packaging brand; and clinical decision support applications. Omnicell serves healthcare providers, pharmacies, hospitals, and long-term care facilities across the United States, Canada, and select international markets. Founded in 1992, the company is headquartered in Mountain View, California. In the past 1-2 years, Omnicell has focused on expanding its clinical and financial analytics capabilities, integrating new software enhancements to improve medication safety and operational workflows. The company has also been active in strategic partnerships that broaden its technology ecosystem and has launched updated versions of its adherence packaging solutions. Omnicell continues to extend its presence in the pharmacy automation market through selective acquisitions and innovation in medication management systems. These initiatives reflect a strategic shift toward comprehensive service offerings that combine hardware, software, and analytics to support a data-driven approach in healthcare operations. Omnicell operates primarily in the healthcare technology and medical devices industry, targeting hospital systems, health systems, retail pharmacies, and senior care providers. Its product and service offerings are designed to address challenges in medication adherence, reduce medication errors, optimize pharmacy workflows, and improve patient outcomes. The company maintains a broad geographic footprint across North America with growing influence internationally, supported by its network of subsidiaries and partners specializing in healthcare technology solutions.

Company News

  • New Strong Buy Stocks for November 5th

  • Best Value Stocks to Buy for November 5th

  • Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

  • Omnicell, Inc. (OMCL) Q3 2026 Earnings Call Transcript

  • Omnicell Q3 Earnings Call Highlights

  • Here's What Key Metrics Tell Us About Omnicell (OMCL) Q3 Earnings

  • Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates

  • Omnicell Announces Third Quarter 2026 Financial Results

  • Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

  • Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)

  • Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

  • Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

  • Here's Why Omnicell (OMCL) is a Strong Value Stock

  • TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

  • Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

  • Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

  • Omnicell President Sells 6,753 Shares

  • Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL

  • Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

  • OMCL Falls 20.1% in a Month as Booking and Margin Risks Build